Clinical Trial Update: A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation study of Locally-Administered OncoGel in recurrent glioma was terminated; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Glioblastoma

Drugs mentioned

• OncoGel

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Glioblastoma Multiforme, Brain Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-05-15